目的 探討苦碟子注射液聯(lián)合替格瑞洛片治療冠心病心絞痛的療效。方法 選取2016年4月-2017年11月武漢市漢口醫(yī)院收治的冠心病心絞痛患者76例為研究對(duì)象，按照隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各38例。對(duì)照組口服替格瑞洛片，90 mg/次，首周2次/d，而后1次/d。治療組在對(duì)照組治療的基礎(chǔ)上靜脈滴注苦碟子注射液，30 mL加入到生理鹽水250 mL中，1次/d。兩組患者均連續(xù)治療4周。觀察兩組的臨床療效和心電圖療效，比較兩組的血液流變學(xué)、心絞痛發(fā)作頻率和持續(xù)時(shí)間。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為78.95%、94.74%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對(duì)照組和治療組的心電圖療效總有效率分別為60.53%、81.58%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血漿比黏度（PSV）、全血黏度（WBV）、血細(xì)胞比容（HCT）、纖維蛋白原（FIB）顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組血液流變學(xué)指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組心絞痛發(fā)作頻率、心絞痛持續(xù)時(shí)間明顯下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 苦碟子注射液聯(lián)合替格瑞洛片治療冠心病心絞痛具有較好的臨床療效，可改善血液流變學(xué)，降低心絞痛發(fā)作頻率和持續(xù)時(shí)間，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the effect of Kudiezi Injection combined with Ticagrelor Tablets in treatment of angina pectoris of coronary heart disease. Methods Patients (76 cases) with angina pectoris of coronary heart disease in Wuhan Hankou Hospital from April 2016 to November 2017 were randomly divided into control and treatment groups, and each group had 38 cases. Patients in the control group were po administered with Ticagrelor Tablets, 90 mg/time, twice daily in the first week, then once daily. Patients in the treatment group were iv administered with Kudiezi Injection on the basis of the control group, 30 mL added into normal saline 250 mL, once daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies and electrocardiogram efficacies were evaluated, hemorheology, the frequency and duration of angina pectoris in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.95% and 94.74%, respectively, and there was difference between two groups (P<0.05). After treatment, the electrocardiogram efficacies in the control and treatment groups were 60.53% and 81.58%, respectively, and there was difference between two groups (P<0.05). After treatment, PSV, WBV, HCT, and FIB in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the hemorheology indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the frequency and duration of angina pectoris in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Kudiezi Injection combined with Ticagrelor Tablets has clinical curative effect in treatment of angina pectoris of coronary heart disease, can improve hemorheology, decrease the frequency and duration of angina pectoris, which has a certain clinical application value.